Vectors with modified initiation codon for the translation of AAV-REP78 useful for production of AAV

• US 9,708,627 B2
• Filed: 01/23/2015
• Issued: 07/18/2017
• Est. Priority Date: 06/21/2006
• Status: Active Grant

• Current Assignee: Uniqure Ip B.V. (uniQure N.V.)
• Original Assignee: Uniqure Ip B.V. (uniQure N.V.)
• Inventors: Hermens, Wilhelmus Theodorus Johannes Maria Christiaan, Bakker, Andrew Christian, Haast, Saskia Jacoba Petronella, Biesmans, Dennis Johan
• Primary Examiner(s): Andres, Janet L
• Assistant Examiner(s): Chestnut, Barry A
• Application Number:
  US14/603,469
• Publication Number:
  US 20150140639A1
• Time in Patent Office: 907 Days
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/14043 viral genome or elements thereof as genetic vectore
• CPC Class Codes: C12N 2710/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
• CPC Class Codes: C12N 2710/14143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/14144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
• CPC Class Codes: C12N 2710/14152 relating to complementing cells and packaging systems for producing virus or viral particles
• CPC Class Codes: C12N 2750/14121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
• CPC Class Codes: C12N 2750/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2750/14143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2750/14151 Methods of production or purification of viral material
• CPC Class Codes: C12N 2750/14152 relating to complementing cells and packaging systems for producing virus or viral particles
• CPC Class Codes: C12N 2800/105 for insects
• CPC Class Codes: C12N 2800/50 Vectors for producing vectors
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The present invention relates nucleic acid constructs for the production of recombinant parvoviral (e.g. adeno-associated viral) vectors in insect cells, to insect cells comprising such constructs and to methods wherein the cells are used to produce recombinant parvoviral virions. The insect cells preferably comprise a first nucleotide sequence encoding the parvoviral rep proteins whereby the initiation codon for translation of the parvoviral Rep78 protein is a suboptimal initiation codon that effects partial exon skipping upon expression in insect cells. The insect cell further comprises a second nucleotide sequence comprising at least one parvoviral (AAV) inverted terminal repeat (ITR) nucleotide sequence and a third nucleotide sequence comprising a sequences coding for the parvoviral capsid proteins.

Claims

1. A first nucleic acid construct comprising a first nucleic acid sequence which encodes both Rep78 and Rep52 proteins from a Rep78 nucleotide sequence;

the first nucleic acid sequence being operably linked to an expression control sequence that includes a promoter that is active in insect cells and is constructed such that both Rep78 and Rep52 proteins are produced upon expression in an insect cell.

2. The nucleic acid construct according to claim 1, wherein the promoter is selected from the group consisting of polyhedron promoter, p10 promoter, p35 promoter, IE-1 promoter and delta-IE1 promoter.

3. The nucleic acid construct according to claim 1 that comprises one polyadenylation sequence at the 3′

end of the first nucleic acid sequence.

4. An insect cell comprising the nucleic acid construct according to claim 1, wherein said nucleic acid construct expresses parvoviral Rep78 and Rep52 proteins.

5. The insect cell according to claim 4, wherein the promoter is selected from the group consisting of polyhedron promoter, p10 promoter, p35 promoter, IE-1 promoter and delta-IE1 promoter.

6. The insect cell according to claim 4, wherein the nucleic acid construct comprises one polyadenylation sequence at the 3′

end of the first nucleic acid sequence.

7. The insect cell according to claim 4 selected from the group consisting of Se301, Seizd2109, Seucr1, sf9, Sf900+, Sf21, Bti-Tn-5b1-4, Mg-1, Tn368, Hzam1, Ha2302, Hz2e5, High five and Express+.

8. The insect cell according to claim 4, further comprising a second nucleotide sequence comprising at least one parvoviral inverted terminal repeat (ITR) nucleotide sequence.

9. The insect cell according to claim 8, further comprising a third nucleotide sequence comprising parvoviral Cap protein coding sequences operably linked to expression control sequences for expression of Cap proteins in the insect cell.

10. The insect cell according to claim 8, wherein the second nucleotide sequence comprises two parvoviral ITR nucleotide sequences.

11. The insect cell according to claim 9, further comprising, in addition to the first nucleic acid construct, a second nucleic acid construct, wherein:

(a) the third nucleotide sequence is comprised in the first nucleic acid construct, and

(b) the second nucleotide sequence is comprised in the second nucleic acid construct.

12. The insect cell according to claim 9, further comprising, in addition to the nucleic acid construct comprising the first nucleic acid sequence which encodes both Rep78 and Rep52 proteins, a second and a third nucleic acid construct, wherein

(a) the second nucleic acid construct comprises the second nucleotide sequence, and

(b) the third nucleic acid construct comprises the third nucleotide sequence.

13. The insect cell according to claim 9, wherein the second nucleotide sequence further comprises a fourth nucleotide sequence encoding a gene product of interest positioned either 3′

or 5′

to the ITR sequence or between two ITR sequences.

14. The insect cell according to claim 13, wherein the fourth nucleotide sequence encoding the gene product of interest is positioned between the two ITR sequences.

15. The insect cell according to claim 13, wherein the gene product of interest is a therapeutic gene product.

16. The insect cell according to claim 15, wherein the therapeutic gene product is selected from the group consisting of Cystic fibrosis transmembrane conductance regulator (CFTR), Factor IX, lipoprotein lipase (LPL), apolipoprotein A1, uridine diphosphate glucuronosyltransferase, Retinitis pigmentosa GTPase Regulator Interacting Protein, a cytokine and an interleukin.

17. The insect cell according to claim 16, wherein the LPL is LPL S447X.

18. The insect cell according to claim 16, wherein the interleukin is Interleukin 10.

19. The insect cell according to claim 13, wherein the second nucleotide sequence comprises a nucleotide sequence encoding one or more of the following marker polypeptides:

green fluorescent protein, Herpes Simplex Virus (HSV) thymidine kinase (TK), hygromycin B phosphotransferase, Tn5 aminoglycoside phosphotransferase, dihydrofolate reductase and CD20.

20. The insect cell according to claim 13, wherein the second nucleotide sequence comprises one or more of the following suicide genes:

Escherichia coli cytosine deaminase, HSV-TK, Cytomegalovirus TK or Varicella-Zoster TK.

21. The insect cell according to claim 13, wherein the second nucleotide sequence comprises a nucleotide sequence encoding Rep78 and/or Rep68.